BIOTECHNOLOGY VALUE FUND L P - 26 Jun 2026 SCHEDULE 13D/A Report for Kymera Therapeutics, Inc. Common Stock, $0.0001 par value per share (KYMR)

Filing manager: BIOTECHNOLOGY VALUE FUND L P
Reporting owner: BVF PARTNERS L P/IL
Security: Kymera Therapeutics, Inc. Common Stock, $0.0001 par value per share
Beneficially owned shares: 5,237,151 shares
Large-stake signal: Form
SCHEDULE 13D/A
Active or control-oriented beneficial ownership filing.
Ownership
6.3%
Beneficial ownership of this reported class.
Shares
5,237,151 shares
Shares beneficially owned as disclosed.
Event date
26 Jun 2026
Date tied to the ownership event or amendment.
Accepted by SEC
26 Jun 2026
EDGAR acceptance date.
How to read this large-stake filing
Schedule 13D/G filings focus on beneficial ownership stakes, not a full portfolio.
Compare this filing with the holder history and issuer page before treating the percentage as a current position.
Use amendments to understand whether the disclosed stake increased, decreased, or changed reporting status.
Class ownership: 6.3%
Symbol: KYMR
Shares outstanding: 83,129,381 shares
SEC form: SCHEDULE 13D/A
Accepted by SEC: 26 Jun 2026, 18:43:40 UTC
Event date: 26 Jun 2026
Prior SEC filing: 15 Dec 2025
Source filing: View source filing

Key filing fact

BIOTECHNOLOGY VALUE FUND L P disclosed 6.3% ownership in Kymera Therapeutics, Inc. Common Stock, $0.0001 par value per share (KYMR) on 26 Jun 2026.

Key facts

BIOTECHNOLOGY VALUE FUND L P filed SCHEDULE 13D/A for Kymera Therapeutics, Inc. Common Stock, $0.0001 par value per share (KYMR).
Disclosed ownership: 6.3%.
Date of event: 26 Jun 2026.

This page turns one Schedule 13D/G filing into a quick large-stake read before the raw reporting-person rows.
Use the linked SEC filing as the source of truth for ownership percentages, shares, and reporting-party details.

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

Reporting persons

Names, ownership percentages, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.

Name	Ownership	Shares owned	Sole voting power	Shared voting power	Signature	Title	CIK
BIOTECHNOLOGY VALUE FUND L P	3.3%	2,712,852	0	2,712,852	/s/ Mark N. Lampert	Mark N. Lampert, Authorized Signatory	0000918923
BVF I GP LLC	3.3%	2,712,852	0	2,712,852	/s/ Mark N. Lampert	Mark N. Lampert, Authorized Signatory	0001803805
BIOTECHNOLOGY VALUE FUND II LP	2.6%	2,124,859	0	2,124,859	/s/ Mark N. Lampert	Mark N. Lampert, Authorized Signatory	0001102444
BVF II GP LLC	2.6%	2,124,859	0	2,124,859	/s/ Mark N. Lampert	Mark N. Lampert, Authorized Signatory	0001803806
Biotechnology Value Trading Fund OS LP	0.4%	292,856	0	292,856	/s/ Mark N. Lampert	Mark N. Lampert, Authorized Signatory	0001660683
BVF Partners OS Ltd.	0.4%	292,856	0	292,856	/s/ Mark N. Lampert	Mark N. Lampert, Authorized Signatory	0001660684
BVF GP HOLDINGS LLC	5.8%	4,837,711	0	4,837,711	/s/ Mark N. Lampert	Mark N. Lampert, Authorized Signatory	0001803809
BVF PARTNERS L P/IL	6.3%	5,237,151	0	5,237,151	/s/ Mark N. Lampert	Mark N. Lampert, Authorized Signatory	0001055947
BVF INC/IL	6.3%	5,237,151	0	5,237,151	/s/ Mark N. Lampert	Mark N. Lampert, Authorized Signatory	0001056807
LAMPERT MARK N	6.3%	5,237,151	0	5,237,151	/s/ Mark N. Lampert	Mark N. Lampert	0001233840
Hrustanovic Gorjan	0.1%	116,190	116,190	0	/s/ Gorjan Hrustanovic	Gorjan Hrustanovic	0001821194

CIK / CUSIP context first

Broader feeds